

11-15-06

JFW 1615

CASE 33284-US-PCT



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 72727422345

Express Mail Label Number

November 14, 2006

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

AUBERSON ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2004/009225

FILED: 17 AUGUST 2004

U.S. APPLICATION NO: 10/568,841

35 USC §371 DATE: 17 FEBRUARY 2006

FOR: 3H-PHENOXAZINE DERIVATIVES SUITABLE AS NEAR-INFRARED
IMAGING AGENTS, PREPARATION AND USE THEREOF**MS: Amendment**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report and since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references are enclosed. US 2004/0029837 is believed to be substantially equivalent to WO 02/20670.


ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7951

Date: *November 14, 2006*

Respectfully submitted,



Peter J. Waibel
Attorney for Applicants
Reg. No. 43,228

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
33284-US-PCT
APPLICATION NO.
10/568,841
APPLICANT
AUBERSON ET AL.
FILING DATE
FEBRUARY 17, 2006

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	2004/0029837	2/12/04	Fries et al.	514	100	9/5/01
	AB	6,329,531	12/11/01	Turner et al.	548	455	10/29/97
	AC	6,447,749	9/10/02	Licha et al.	424	9.1	9/29/00
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	*1 193 260	4/3/02	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AN	0 885 263	4/25/01	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AO	00/10614	3/2/00	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	*Wischik C M et al., "Selective Inhibition of Alzheimer Disease-Like Tau Aggregation by Phenothiazines", Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, US, pp. 11213-11218, (1996).
	AS	*H. Michael Petrassi et al., "Structure-based Design of N-Phenyl Phenoxazine Transthyretin Amyloid Fibril Inhibitors", Journal of the American Chemical Society, Vol. 122, no. 10, pp. 2178-2179, (2000).
	AT	Bacskai Brian J et al., "Imaging Amyloid- β Deposits In Vivo", Journal of Cerebral Blood Flow & Metabolism, Vol 22, pp.1035-1041, (2002).

EXAMINER

/Kahsay Habte/

DATE CONSIDERED

06/29/2009

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/